This article is more than 5 years old. Information may no longer be current.

Medtronic buys aqueous stent for glaucoma treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MINNEAPOLIS — Medtronic has bought the rights to an investigational aqueous stent for the treatment of glaucoma, the company announced last week. Clinical trials of the CellPlant Aqueous Stent will begin once Medtronic has received Food and Drug Administration approval to commence, the company announced.

The CellPlant stent is made with a proprietary polymer that may be better accepted by human tissue than currently available glaucoma shunt devices, according to a press release from the company.

“The polymer is intended to prevent cell adhesion and create a permanent opening that improves fluid outflow from the eye,” according to the press release. “The new stent is intended to eliminate the need for a filtering bleb.”

According to Medtronic, the stent is implanted during a standard trabeculectomy, positioned beneath the trabecular flap. The stent is intended to increase flow rate as the patient’s IOP builds.